Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Baylor College of Medicine
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of Iowa
Columbia University
Case Comprehensive Cancer Center
Dana-Farber Cancer Institute
Ludwig Institute for Cancer Research
Ludwig Institute for Cancer Research
Imperial College London
Weill Medical College of Cornell University
Emory University
University of California, Irvine
Shanghai Junshi Bioscience Co., Ltd.
Jonsson Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Osaka University
Alliance for Clinical Trials in Oncology
Dana-Farber Cancer Institute
University of Chicago
Memorial Sloan Kettering Cancer Center
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Northwestern University
Medical University of South Carolina
Ohio State University Comprehensive Cancer Center
Dana-Farber Cancer Institute
Duke University
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Virginia Commonwealth University
M.D. Anderson Cancer Center
Northwestern University
Medical University of South Carolina
The Cleveland Clinic
Ohio State University Comprehensive Cancer Center
Indiana University
Yale University
University of Chicago
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Duke University
Jonsson Comprehensive Cancer Center
Mayo Clinic